Navigation Links
Endo Pharmaceuticals Reports Strong Fourth Quarter and Full-Year 2009 Financial Results: Provides 2010 Financial Guidance
Date:2/22/2010

rations: (1) To exclude amortization of commercial intangible assets related to marketed products. (2) To exclude upfront and milestone payments to partners. (3) To exclude purchased in-process research and development. (4) To exclude additional interest expense as a result of adopting ASC 470-20. (5) To exclude changes in fair value of financial instruments, net. (6) To reflect the tax effect of the pre-tax adjustments above at the applicable tax rates.

The following tables provide a reconciliation of our reported (GAAP) statements of operations to our adjusted statements of operations for each of the year ended Dec. 31, 2009 and Dec. 31, 2008 (Certain prior period amounts have been adjusted to reflect the retrospective adoption of accounting guidance pursuant to ASC 470-20: Debt With Conversion and Other Options (formerly referred to as FSP APB 14-1) and to conform to the current period presentation) (in thousands, except per share data):

    
    
    
                               Actual
    Year Ended Dec. 31,       Reported
     2009 (unaudited)          (GAAP)    Adjustments          Adjusted
                              --------   -----------          --------
    Total Revenues          $1,460,841             -        $1,460,841
    Costs and expenses:
      Cost of revenues         375,058       (74,199)   (1)    300,859
      Selling, general and
       administrative          534,523        (2,549)   (2)    531,974
      Research and
       development             185,317       (77,099)   (3)    108,218
      Impairment of
       intangibles              69,000       (69,000)   (4)          -
      Acqui
'/>"/>
SOURCE Endo Pharmaceuticals
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24

Related medicine technology :

1. Auxilium Pharmaceuticals, Inc. Receives Clearance to Resume Clinical Trials for XIAFLEX(TM)
2. Vion Pharmaceuticals Completes Accrual of 85 Patients to its Pivotal Phase II Trial of Cloretazine(R) (VNP40101M) in Elderly AML
3. Solvay Pharmaceuticals, Inc. and Wyeth Pharmaceuticals Announce Receipt of an FDA Action Letter for Bifeprunox, an Investigational Treatment for Schizophrenia
4. Callisto Pharmaceuticals Opens Additional Sites for Phase II Clinical Trial of Atiprimod in Advanced Carcinoid Cancer Patients
5. WallSt.net (www.wallst.net) Updates the Investment Community Through an All-New Interview With RegeneRx Biopharmaceuticals CEO
6. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
7. Peregrine Pharmaceuticals Doses First Patient in Cotara(R) Phase II Brain Cancer Trial In India
8. Nabi Biopharmaceuticals Announces Second Quarter 2007 Financial Results
9. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
10. Quark Pharmaceuticals Extends Research Agreement with State University of New York for Proprietary siRNA Compounds for Acute Hearing Loss
11. Acura Pharmaceuticals, Inc. Secures Financing to Fund Pivotal Phase III Clinical Trial for Lead Aversion(R) Technology Product Candidate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014 Most osteoporosis patients ... to a recent online survey* sponsored by Mission Pharmacal ... the National Osteoporosis Foundation online support community, revealed that ... medication that comes in a form other than a ...
(Date:1/15/2014)... Jan. 15, 2014  Celsion Corporation (the "Company") (NASDAQ: ... from institutional investors to purchase an aggregate of approximately ... at-the-market registered direct offering, led by a dedicated health ... purchase agreements with these investors pursuant to which the ...
(Date:1/15/2014)...  Manufacturers, suppliers and distributors of innovative medical-related products ... most important business assets, intellectual property (IP). ... Because of the highly-competitive nature of the Medical ... most litigious industry sectors of cases involving IP ...
Breaking Medicine Technology:Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 2Mission Pharmacal Conducts Online Survey of Osteoporosis Patients 3Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 2Celsion Corporation Announces $15 Million At-The-Market Registered Direct Offering 3Intellectual Property Insurance for Medical-related Products and Services 2
... CITY, Feb. 21, 2012 Genomma Lab Internacional, S.A.B. de ... a non-binding proposal to acquire all of the outstanding shares ... ) common stock for $16.60 dollars per share in cash. ... including Prestige,s net debt. Genomma,s all-cash proposal ...
... Corporation (NYSE: SHP ) ("ShangPharma" or the ... development outsourcing company, today announced that it will attend ... in Boston, Massachusetts from March 5-7, 2012. ... Relations of ShangPharma, will present at the conference and ...
Cached Medicine Technology:Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 2Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 3Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 4Genomma Lab Internacional Announces Non-binding Proposal to Acquire Prestige Brands Holdings for $16.60 Per Share in Cash 5
(Date:4/18/2014)... University School of Medicine researchers have been awarded two-year ... Novo Nordisk announced this month. Of the 110 initial ... Biologics Science Forum Program, only four projects were funded, ... They are Jonathan Powell, M.D., Ph.D.; G. William Wong, ... Powell, a professor of oncology, will use his $500,000 ...
(Date:4/18/2014)... Fraser University psychologists have made a brain-related discovery ... attention-deficit disorders. , This discovery opens up the ... or suppress a specific brain activity that the ... , The Journal of Neuroscience has ... John McDonald, an associate professor of psychology and ...
(Date:4/18/2014)... to potential new treatments for breaking the cycle of ... or scarring, is a hallmark of the disease, and ... to serious organ damage and, in some cases, death. ... findings made by Swati Bhattacharyya, PhD, research assistant professor ... protein plays in promoting fibrosis. , "Our results ...
(Date:4/17/2014)... identified the first genetic variant specifically associated with ... for around 10-15 per cent of all breast ... the breast cancer sub-type, called invasive lobular carcinoma, ... of this particular kind of breast cancer, which ... published today (Thursday) in the journal PloS ...
(Date:4/17/2014)... today in PLOS Pathogens , children who live ... can mount an immune response to infection with malaria ... of high fever and illness and partially control the ... may help researchers develop future interventions that prevent or ... Each year, approximately 200 million cases of malaria occur ...
Breaking Medicine News(10 mins):Health News:Scientists discover brain's anti-distraction system 2Health News:New clues on tissue scarring in scleroderma 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 2Health News:First genetic link discovered to difficult-to-diagnose breast cancer sub-type 3Health News:Study sheds light on how the immune system protects children from malaria 2
... 23 (HealthDay News) -- Implantable devices designed to ... death among heart failure patients are as effective ... they are in controlled study environments, new research ... analysis of nearly 186,000 patients outfitted with either ...
... Richmond, Va. (Nov. 22, 2010) Researchers at Virginia ... for its involvement in tumor cell development, growth and ... chemotherapy. By inhibiting the expression of this gene, doctors ... treating aggressive cancers such as breast, liver and prostate ...
... Elderly adults can improve their vision with perceptual training, according ... Boston University that has implications for the health and mobility ... improved visual performance in early stages of visual processing," appears ... Vision . It was funded by a $3.5 million grant ...
... News) -- Increased efforts to prevent several lifestyle-related diseases ... year in medical costs, researchers say. Using 2003-2005 ... estimated how reductions in the rates of diabetes, high ... spending. The findings were released online Nov. 18 ...
... HealthDay Reporter , MONDAY, Nov. 22 (HealthDay ... therapy with either warfarin or a combination of Plavix ... Both therapies are prescribed for millions of Americans ... attack or stroke. But the Plavix-aspirin combination was thought ...
... and droplets are the primary ways influenza spreads. ... In a study published in the current issue ... ( http://www.journals.uchicago.edu/doi/abs/10.1086/656743 ), the authors examined such an ... On April 4, 2008, seven inpatients in ...
Cached Medicine News:Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 2Health News: Implanted Heart Devices Have 'Real-World' Benefits: Study 3Health News:New function of gene in promoting cancer found by VCU researchers 2Health News:Perceptual training improves vision of the elderly 2Health News:Disease Prevention Could Save U.S. Billions of Dollars Annually 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 2Health News: Bleeding Risk With Plavix-Aspirin Regimen May Be Serious 3
... Bird and Cronin, Inc. ... of Patient Footwear, Orthopedic ... Care Products. Our products ... quality and available in ...
... AliMed® Turnbuckle Ankle Orthosis enables ... torque at the ankle joint to ... The splint features a pair of ... and eversion/inversion simultaneously. Simply adjust the ...
Softsplint after bunion surgery. Hook-and-loop closure. Maintains hallux positioning and metatarsophalangeal alignment. Washable....
... vein thrombosis, the Aircast VenaFlow System uses ... and rapid impulse inflation. This combination helps ... while producing more shear stress to enhance ... tube assembly (cuffs are sold separately). The ...
Medicine Products: